SEC Has Started Formal Investigation of Vioxx®

Return to Vioxx® homepage on SSEM.COM

Merck & Co. said the U.S. Securities and Exchange Commission has started a formal probe into its handling of Vioxx®, the painkiller pulled from the market last September because of its link to heart attacks and strokes. Previously, Merck said the SEC was conducting an informal investigation.

The SEC's decision wasn't unexpected the company said in a recent statement. A formal probe gives the SEC the power to issue subpoenas for documents or testimony.

Merck wouldn't comment on the SEC matter beyond the press release, company spokesman Tony Plohoros said.

The news sent Merck shares down 8.6 percent to $28.50.

If you believe that you or a relative were injured by taking Vioxx® please use the form below to contact our law firm.

Have you suffered a heart attack or stroke? (Select Yes or No)
YES
NO

Your Name:

Your E-Mail:

Your Daytime Phone Number:

Your Evening Phone Number:

Please fill in your question or comments:

References

Copyright © 1999-2008 Specter Specter Evans & Manogue, P.C.
Terms of Use | Privacy Policy